Physician profile
John K Shekleton
NPI 1649277666
$3,755.90
in general payments reported to CMS, 2019-2025
21 companies · $41.58 in 2025
The $41.58 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $840 · 2021: $1,027 · 2022: $372 · 2023: $150 · 2024: $586 · 2025: $41.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.24 | 2019-2024 | Creon, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $850.03 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $198.60 | 2019-2024 | Livdelzi |
| Ferring Pharmaceuticals INC. | $189.12 | 2019-2020 | |
| Madrigal Pharmaceuticals | $187.19 | 2024-2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $130.84 | 2019-2021 | |
| Janssen Biotech, INC. | $111.95 | 2019-2022 | |
| Redhill Biopharma INC. | $107.05 | 2020-2021 | |
| Braintree Laboratories, INC. | $93.84 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $88.78 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $77.67 | 2021 | |
| Merck Sharp & Dohme LLC | $72.54 | 2021-2022 | |
| Qol Medical, LLC | $63.44 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $62.87 | 2019-2020 | |
| Pfizer INC. | $43.96 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.49 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $25.62 | 2024 | Voquezna |
| Csl Behring | $22.53 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.83 | 2024 | Iqirvo |
| Allergan, INC. | $17.52 | 2020 | |
| Celgene Corporation | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shekleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.